BBCVirtus LifeSci Biotech Clinical Trials ETF
Seeks investment results that correspond to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index.
By Virtus · Launched 2014
Annual Cost
0.65%
#3,547 of 6,040 · average
Fund Size
$50M
#3,742 of 6,040 · mid-size
Return (1Y)
+107.6%
Track Record
11 years
#1,250 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$17,873+78.7%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
LifeSci Biotechnology Clinical Trials Index
Holdings
By weightConcentration
Top 10 holdings = 17.1% of funddiversified
DREYFUS GOVERNMENT CASH MANAGEDGCXX
2.3%
ERASCA INC
2.2%
ENLIVEN THERAPEUTICS INC
1.8%
TANGO THERAPEUTICS INC
1.7%
ORUKA THERAPEUTICS INC
1.7%
SPYRE THERAPEUTICS INC
1.6%
ALUMIS INC
1.6%
DIANTHUS THERAPEUTICS INC
1.5%
KODIAK SCIENCES INC
1.3%
REVOLUTION MEDICINES INC
1.3%
Asset allocation
Stocks
99.9%
Cash
0.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
36.9%High
Year-on-year price swings
Max drawdown
-76.8%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.85Decent risk-adjusted returns
Sortino (3Y)
1.25Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks investment results that correspond to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index.
- Strategy
- Invests primarily in common stock of U.S. biotechnology companies with lead drugs in clinical trials, using a passive indexing approach to replicate the LifeSci Biotechnology Clinical Trials Index. Concentrates investments in the biotechnology sector, targeting companies with market capitalizations of at least $250 million.
- Inception date
- December 16, 2014
- Fund family
- Virtus
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save BBC to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18